Last reviewed · How we verify
StromaForte
At a glance
| Generic name | StromaForte |
|---|---|
| Sponsor | Cellcolabs Clinical SPV Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and/or Degeneration (PHASE1, PHASE2)
- A Study to Evaluate Mesenchymal Stem Cell Product StromaForte's Effect on Cardiovascular Events (PHASE1, PHASE2)
- A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging Frailty (PHASE1, PHASE2)
- A Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte for the Treatment of Knee Osteoarthritis (PHASE1, PHASE2)
- A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- StromaForte CI brief — competitive landscape report
- StromaForte updates RSS · CI watch RSS
- Cellcolabs Clinical SPV Limited portfolio CI